R
Richard N. Fedorak
Researcher at University of Alberta
Publications - 405
Citations - 32918
Richard N. Fedorak is an academic researcher from University of Alberta. The author has contributed to research in topics: Inflammatory bowel disease & Infliximab. The author has an hindex of 78, co-authored 405 publications receiving 29843 citations. Previous affiliations of Richard N. Fedorak include Columbia University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
William J. Sandborn,Brian G. Feagan,Paul Rutgeerts,Stephen B. Hanauer,Jean-Frederic Colombel,Jean-Frederic Colombel,Bruce E. Sands,Milan Lukas,Richard N. Fedorak,Scott D. Lee,Brian Bressler,I. Fox,Maria Rosario,Serap Sankoh,Jing Xu,Kristin Stephens,Catherine Milch,Asit Parikh +17 more
TL;DR: Vedolizumab-treated patients with active Crohn's disease were more likely than patients receiving placebo to have a remission, but not a CDAI-100 response, at week 6; patients with a response to induction therapy who continued to receive vedolIZumab (rather than switching to placebo) were morelikely to be in remission at week 52.
Journal ArticleDOI
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
Bruce E. Sands,Frank H. Anderson,Charles N. Bernstein,William Y. Chey,Brian G. Feagan,Richard N. Fedorak,Michael A. Kamm,Joshua R. Korzenik,Bret A. Lashner,Jane E. Onken,Daniel Rachmilewitz,Paul Rutgeerts,Gary Wild,Douglas C. Wolf,Paul Marsters,Suzanne Travers,Marion Blank,Sander J. H. van Deventer +17 more
TL;DR: Patients with fistulizing Crohn's disease who have a response to induction therapy with inflIXimab have an increased likelihood of a sustained response over a 54-week period if infliximab treatment is continued every 8 weeks.
Journal ArticleDOI
Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial
Stephen B. Hanauer,William J. Sandborn,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,Paul F. Pollack +8 more
TL;DR: Adalimumab was superior to placebo for induction of remission in patients with moderate to severe Crohn's disease naive to anti-TNF therapy and was well tolerated.
Journal ArticleDOI
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
William J. Sandborn,Stephen B. Hanauer,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,J. D. Kent,Barry Bittle,Ju Li,Paul F. Pollack +11 more
TL;DR: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn’s disease naive to anti-TNF treatment in a follow-on randomised controlled trial.
Journal ArticleDOI
Methotrexate for the Treatment of Crohn's Disease
Brian G. Feagan,J. Rochon,Richard N. Fedorak,E J Irvine,Gary Wild,Lloyd R. Sutherland,A H Steinhart,Gordon R. Greenberg,R Gillies,Marybeth Hopkins +9 more
TL;DR: In a group of patients with chronically active Crohn's disease, methotrexate was more effective than placebo in improving symptoms and reducing requirements for prednisone.